...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BJU international >Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
【24h】

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.

机译：激素难治性前列腺癌患者循环上皮细胞的评估及其意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To determine the feasibility of using flow cytometry fluorescence-activated cell sorting (FACS) analysis for detecting circulating epithelial cells (CECs) in patients with hormone-refractory prostate cancer (HRPC), and to determine whether CECs can be used to predict survival in these patients. PATIENTS AND METHODS: Several prognostic models that include routinely used clinical and laboratory variables for predicting survival in men with HRPC have been reported; the presence of CECs measured by reverse transcriptase-polymerase chain reaction for prostate-specific antigen (PSA) in patients with HRPC is an independent prognostic factor for survival. CECs detected by FACS analysis correlate with advanced stage and poor survival outcome. A retrospective study was conducted to assess the presence of CECs by FACS analysis in metastatic HRPC patients initiating systemic chemotherapy with a taxane-based regimen. The association between clinical variables previously described and the presence of CECsalong with the effect of the magnitude of CECs on survival was calculated, in 41 patients with HRPC, all of whom had peripheral blood collected for FACS analysis. RESULTS: Except for four patients, all those with metastatic HRPC had detectable CECs. Among these patients, the number of CECs/mL was correlated with age, serum PSA level and serum alkaline phosphatase (ALP). Higher serum levels of PSA and ALP predicted a poor survival outcome. Similarly, patients with < or =1.8 CECs/mL had a significantly longer survival than those with more CECs/mL (P = 0.02). With a median follow-up of 15.4 months, the median overall survival for all patients was 18.4 months. CONCLUSIONS: The presence of more CECs in patients with metastatic HRPC was associated with a poorer survival outcome; levels of > or =1.8 CECs/mL were associated with a shorter survival in patients with metastatic HRPC.
机译：目的：确定使用流式细胞术荧光激活细胞分选（FACS）分析检测激素难治性前列腺癌（HRPC）患者中循环上皮细胞（CEC）的可行性，并确定是否可以使用CEC预测存活率在这些患者中。患者和方法：已经报道了几种预后模型，其中包括常规使用的临床和实验室变量来预测HRPC男性的生存。 HRPC患者中通过前列腺特异性抗原（PSA）的逆转录酶-聚合酶链反应测量的CEC的存在是生存的独立预后因素。通过FACS分析检测到的CEC与晚期阶段和较差的生存结果相关。进行了一项回顾性研究，以通过FACS分析评估以紫杉烷为基础的方案开始全身化疗的转移性HRPC患者中CEC的存在。在41例HRPC患者中，计算了先前描述的临床变量与CEC的存在与CEC幅度对生存的影响之间的关联，这些患者均采集了外周血用于FACS分析。结果：除四名患者外，所有转移性HRPC患者均具有可检测的CEC。在这些患者中，CECs / mL的数量与年龄，血清PSA水平和血清碱性磷酸酶（ALP）相关。较高的血清PSA和ALP水平预示了不良的生存结果。同样，CECs≤1.8的患者比CECs / mL更高的患者具有更长的生存期（P = 0.02）。中位随访期为15.4个月，所有患者的中位总生存期为18.4个月。结论：转移性HRPC患者中存在更多的CECs与较差的生存结果有关。 ≥1.8 CECs / mL的水平与转移性HRPC患者的生存期较短有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号